| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SION | Common Stock | Conversion of derivative security | +3,154,959 | 3,154,959 | 10 Feb 2025 | See footnotes | F1, F3, F4 | |||
| transaction | SION | Common Stock | Purchase | $9,900,000 | +550,000 | +17% | $18.00 | 3,704,959 | 10 Feb 2025 | See footnotes | F2, F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SION | Series B convertible preferred stock | Conversion of derivative security | $0 | -2,560,951 | -100% | $0.000000 | 0 | 10 Feb 2025 | Common Stock | 1,752,755 | See footnotes | F1, F3, F4 | |
| transaction | SION | Series C convertible preferred stock | Conversion of derivative security | $0 | -2,048,760 | -100% | $0.000000 | 0 | 10 Feb 2025 | Common Stock | 1,402,204 | See footnotes | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |
| F2 | Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering. |
| F3 | These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. |
| F4 | This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. |